Skip to main content
Xbrane Biopharma logo

Xbrane Biopharma — Investor Relations & Filings

Ticker · XBRANE ISIN · SE0007789409 LEI · 5493008DKD05APTKQO39 ST Manufacturing
Open in API
Filings indexed 361 across all filing types
Latest filing 2026-06-03 Regulatory Filings
Country SE Sweden
Listing ST XBRANE

About Xbrane Biopharma

https://xbrane.com/en/

Xbrane Biopharma is a biotechnology company that specializes in the development of biosimilars—follow-on versions of approved biological drugs. The company's mission is to enhance the accessibility of biological treatments for serious diseases by creating more affordable alternatives. Xbrane utilizes a patented platform technology and efficient manufacturing systems, employing both bacterial and mammalian cells, to achieve lower production costs. Its development pipeline includes several biosimilar candidates, with a key product being a ranibizumab biosimilar.

Recent filings

Filing Released Lang Actions
Xbrane Biopharma AB (publ) (”Xbrane” eller ”Bolaget”) (Nasdaq Stockholm: XBRANE) erhåller FDA beslutsdatum (BsUFA) den 29 oktober 2026 för sin biosimilarkandidat till LUCENTIS® (ranibizumab)
Regulatory Filings Classification · 75% confidence The document is a press release announcing that Xbrane Biopharma’s BLA resubmission has been accepted by the FDA with a BsUFA decision date. It does not contain financial results, management changes, voting results, or other specific categories. It is a general regulatory announcement about a product approval timeline. Hence it falls under Regulatory Filings (RNS) as a fallback for miscellaneous regulatory announcements.
2026-06-03 Swedish
Xbrane Biopharma AB (publ) (“Xbrane” or “the Company”) (Nasdaq Stockholm: XBRANE) receives FDA BsUFA date of October 29, 2026 for its investigational biosimilar candidate to LUCENTIS® (ranibizumab)
Regulatory Filings Classification · 82% confidence The document is a press release announcing FDA acceptance of a resubmitted Biologics License Application and a BsUFA action date. It contains no financial statements, management discussion, or voting information. It is a required market disclosure under EU Market Abuse Regulation but not an earnings release, annual or interim report, or other specific filing type. Therefore, it falls under general Regulatory Filings (RNS).
2026-06-03 English
Kommuniké från årsstämma i Xbrane Biopharma AB
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a press release dated May 5, 2026, reporting on the Annual General Meeting (AGM) of Xbrane Biopharma AB. It details decisions made at the AGM, including approval of financial statements, discharge of board and CEO, election of board members and auditors, approval of remuneration report, adoption of remuneration guidelines, and authorization for share issuance. The document is a summary communication of the AGM outcomes rather than the full AGM materials or presentations. It is not a full annual report or financial report but a formal announcement of AGM decisions. Therefore, it fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is 4353 characters, which is consistent with a detailed announcement but not a full report or presentation.
2026-05-05 English
Announcement from the annual general meeting in Xbrane Biopharma AB
AGM Information Classification · 95% confidence The document is a press release dated 5 May 2026, announcing the resolutions passed at the Annual General Meeting (AGM) of Xbrane Biopharma AB. It includes details such as adoption of income statement and balance sheet, allocation of profit, discharge from liability, election of board members and auditors, approval of remuneration report, adoption of remuneration guidelines, and authorization for the board to issue shares. The content is typical of an AGM announcement summarizing the meeting outcomes rather than the full AGM materials or the annual report itself. The document length is 4894 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, the appropriate classification is AGM Information (AGM-R).
2026-05-05 English
Interim / Quarterly Report 2026
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Interim Report January – March 2026' and contains detailed financial data for the first quarter of 2026, including revenue, EBITDA, R&D costs, earnings per share, cash flow, and other financial metrics. It also includes a CEO letter discussing business operations, product portfolio updates, and financial position. The presence of comprehensive financial statements and analysis for a quarter, along with management commentary, clearly identifies this as a quarterly financial report. The document length is substantial (15,000 characters), and it contains actual financial data rather than just an announcement or certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q1 2026
2026-05-05 English
Valuation expert Venture Valuation provides external valuation of Xdivane program
Regulatory Filings Classification · 95% confidence The document is a press release dated May 5, 2026, from Xbrane Biopharma announcing an external valuation of their Xdivane program by Venture Valuation. It provides detailed assumptions and valuation figures but does not contain financial statements, regulatory filings, or management discussion of financial results. The document is relatively short (3255 characters) and serves as an announcement of a valuation rather than a comprehensive financial report or regulatory filing. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. It is not a report publication announcement either, as it does not mention the release or availability of a report. The content is best classified as a general regulatory announcement or miscellaneous filing that does not fit other categories, which corresponds to Regulatory Filings (RNS).
2026-05-05 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.